Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Monoclonal Antibody
100%
Relapsed or Refractory
100%
New Frontiers
100%
Refractory Diffuse Large B-cell Lymphoma
100%
Immune Response
40%
Cancer Cells
20%
Mechanism of Action
20%
Tumor Cells
20%
Therapeutic Strategies
20%
Aggressive Lymphoma
20%
Unmet Needs
20%
Chemorefractoriness
20%
Lymphoma Patients
20%
Antibody-dependent Cellular Cytotoxicity
20%
Complement-dependent Cytotoxicity
20%
Therapeutic Potential
20%
Frontline Treatment
20%
Relapsed Disease
20%
Bystander
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
20%
Cell Treatment
20%
Radionuclides
20%
R-CHOP
20%
Antibody-drug Conjugate
20%
Radioimmunotherapy
20%
Patient Experience
20%
Chimeric Antigen Receptor T Cells (CAR-T)
20%
Anticancer Strategy
20%
Immune Checkpoint Inhibitors
20%
Bispecific T-cell Engager (BiTE)
20%
Targeted Cells
20%
Novel Antibodies
20%
Primary Refractory Disease
20%
Cytotoxic Payload
20%
Antibody-dependent Cellular Phagocytosis
20%
Beta Emitters
20%
Primary Non-responder
20%
Medicine and Dentistry
Monoclonal Antibody
100%
Diffuse Large B-Cell Lymphoma
100%
Immune Response
33%
Diseases
33%
Malignant Neoplasm
16%
T Cell
16%
Radioisotope
16%
Cancer Cell
16%
Tumor Cell
16%
Phagocytosis
16%
Antibody Dependent Cellular Cytotoxicity
16%
Aggressive Lymphoma
16%
Autologous Stem Cell Transplantation
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Radioimmunotherapy
16%
Patient Experience
16%
Immune Checkpoint Inhibitor
16%
Chimeric Antigen Receptor T-Cell
16%
Complement Dependent Cytotoxicity
16%
Immunology and Microbiology
Monoclonal Antibody
100%
B Cell
100%
Immune Response
33%
T Cell
16%
Tumor Cell
16%
Cancer Cell
16%
Phagocytosis
16%
Immunity
16%
Antibody-Dependent Cell-Mediated Cytotoxicity
16%
Autologous Stem Cell Transplantation
16%
Complement Dependent Cytotoxicity
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Chimeric Antigen Receptor T-Cell
16%
Pharmacology, Toxicology and Pharmaceutical Science
Monoclonal Antibody
100%
Diffuse Large B Cell Lymphoma
100%
Malignant Neoplasm
33%
Cytotoxicity
33%
Diseases
33%
Neoplasm
16%
Radioisotope
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Immune Checkpoint Inhibitor
16%